期刊
ARCHIVES OF MEDICAL RESEARCH
卷 46, 期 5, 页码 392-407出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.arcmed.2015.05.007
关键词
Coronary artery disease; Dyslipidemias; Inflammation; Microbiota; Nonalcoholic fatty liver; Osteopontin; Osteoprotegerin
资金
- CONACYT [233493]
Metabolic syndrome (MetS) should be considered a clinical entity when its different symptoms share a common etiology: obesity/insulin resistance as a result of a multiorgan dysfunction. The main interest in treating MetS as a clinical entity is that the addition of its components drastically increases the risk of atherosclerosis. In MetS, the adipose tissue plays a central role along with an unbalanced gut microbiome, which has become relevant in recent years. Once visceral adipose tissue (VAT) increases, dyslipidemia and endothelial dysfunction follow as additive risk factors. However, when the nonalcoholic fatty liver is present, risk of a cardiovascular event is highly augmented. Epicardial adipose tissue (EAT) seems to increase simultaneously with the VAT. In this context, the former may play a more important role in the development of the atherosclerotic plaque than the latter. Hence, EAT may act as a paracrine tissue vis-a-vis the coronary arteries favoring the local inflammation and the atheroma calcification. (C) 2015 IMSS. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据